Stiff person syndrome and cerebellar ataxia associated with glutamic acid decarboxylase antibodies and type 1 diabetes: What is the link between neurological diseases and autoimmunity to the beta cell?

[1]  R. Tisch,et al.  Central Nervous System Destruction Mediated by Glutamic Acid Decarboxylase-Specific CD4+ T Cells , 2010, The Journal of Immunology.

[2]  C. Auffray,et al.  Specific gene expression signature associated with development of autoimmune type-I diabetes using whole-blood microarray analysis , 2010, Genes and Immunity.

[3]  R. Planas,et al.  Gene expression profiles for the human pancreas and purified islets in Type 1 diabetes: new findings at clinical onset and in long‐standing diabetes , 2010, Clinical and experimental immunology.

[4]  S. Richardson,et al.  Analysis of islet inflammation in human type 1 diabetes , 2009, Clinical and experimental immunology.

[5]  L. Ramió-Torrentá,et al.  Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. , 2008, Brain : a journal of neurology.

[6]  H. Weiner,et al.  Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. , 2008, The Journal of clinical investigation.

[7]  C. Hampe,et al.  Immunobiology of Stiff-Person Syndrome , 2008, International reviews of immunology.

[8]  J. Honnorat,et al.  Effects of anti–glutamic acid decarboxylase antibodies associated with neurological diseases , 2007, Annals of neurology.

[9]  H. Mitoma,et al.  Selective loss of Purkinje cells in a patient with anti-glutamic acid decarboxylase antibody-associated cerebellar ataxia , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  Timothy W Behrens,et al.  Gene expression profiling in human autoimmunity , 2006, Immunological reviews.

[11]  Bruce T Lahn,et al.  Trak1 mutation disrupts GABAA receptor homeostasis in hypertonic mice , 2006, Nature Genetics.

[12]  C. Wessig,et al.  Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin , 2005, The Lancet.

[13]  B. Giometto,et al.  Antigenic differences between neurological and diabetic patients with anti‐glutamic acid decarboxylase antibodies , 2005, European journal of neurology.

[14]  R. Planas,et al.  Islet-infiltrating B-cells in nonobese diabetic mice predominantly target nervous system elements. , 2005, Diabetes.

[15]  J. Verdaguer,et al.  Diabetes mellitus tipo 1: autoinmunidad frente a la célula beta , 2004 .

[16]  C. Liddle,et al.  The histopathology of the pancreas in Type I (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom , 1986, Diabetologia.

[17]  D. Becker,et al.  Autoimmune islet destruction in spontaneous type 1 diabetes is not β-cell exclusive , 2003, Nature Medicine.

[18]  R. Casamitjana,et al.  T‐cell reactivity to glutamic acid decarboxylase in stiff‐man syndrome and cerebellar ataxia associated with polyendocrine autoimmunity , 2002, Clinical and experimental immunology.

[19]  M. Dalakas,et al.  High-dose intravenous immune globulin for stiff-person syndrome. , 2001, The New England journal of medicine.

[20]  A. Vighetto,et al.  Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. , 2001, Archives of neurology.

[21]  L. Chatenoud,et al.  Tolerance to islet autoantigens in type 1 diabetes. , 2001, Annual review of immunology.

[22]  C. Beaufort.  Variation and trends in incidence of childhood diabetes in Europe , 2000, The Lancet.

[23]  Bhagirath Singh,et al.  The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. , 1997, Immunity.

[24]  E. Kirches,et al.  Stiff-man syndrome: possible autoimmune etiology targeted against GABA-ergic cells. , 1997, Clinical neuropathology.

[25]  M. Atkinson,et al.  Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. , 1996, Journal of immunology.

[26]  J. Todd.  Genetic analysis of type 1 diabetes using whole genome approaches. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Ariza,et al.  Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. , 1994, Journal of immunology.

[28]  S. Baekkeskov,et al.  Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus , 1994, The Journal of experimental medicine.

[29]  P. De Camilli,et al.  Association of HLA-DQB1*0201 with stiff-man syndrome. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  O. Simell,et al.  Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. , 1992, The Journal of clinical investigation.

[31]  K. McEvoy,et al.  Stiff-Man Syndrome , 1991, Mayo Clinic proceedings.

[32]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[33]  P. De Camilli,et al.  Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. , 1990, The New England journal of medicine.

[34]  S. Baekkeskov,et al.  Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase , 1990, Nature.

[35]  F. Howard,et al.  Stiff-man syndrome updated. , 1989, Mayo Clinic proceedings.